Irlab Therapeutics Ab Stock Net Income
| IRLAB-A Stock | SEK 1.64 0.05 3.14% |
Momentum 43
Sell Extended
Oversold | Overbought |
As of the 10th of March, IRLAB Therapeutics trades at 1.64 per share. Key technical indicators include Risk Adjusted Performance of -0.07, coefficient of variation of -954.06, and Market Risk Adjusted Performance of 0.6133. The technical model evaluates historical price movement, trading volume, and volatility patterns to quantify trend strength. Current values are evaluated relative to sector peers and historical ranges.
IRLAB Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time.IRLAB Therapeutics AB does not currently have any fundamental trend indicators for analysis. Continue to Equity Screeners for broader equity screening tools. This adds neutral context for broader instrument coverage.IRLAB |
IRLAB Therapeutics 'What if' Analysis
Running a what-if backtest on IRLAB Therapeutics AB gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether IRLAB Therapeutics' historical reward profile was stable enough to support the current thesis.
| 12/10/2025 |
| 03/10/2026 |
If you invested 0.00 in IRLAB Therapeutics on December 10, 2025 and closed the position today, you would earn 0.00 in total gains. That corresponds to a 0.0% return on investment in IRLAB Therapeutics overall over 90 days.. IRLAB Therapeutics is related to or competes with Lipum AB, Isofol Medical, Bio Works, Karolinska Development, Initiator Pharma, Annexin Pharmaceuticals, and Xbrane Biopharma. Peer context helps frame relative positioning. IRLAB Therapeutics AB operates as a drug discovery and development company that provides drugs in the field of neurologi... More
IRLAB Therapeutics Upside and Downside Indicators Overview
Upside and downside indicators for IRLAB Therapeutics summarize momentum balance and potential range context for the stock. They compare current price to recent trend and sentiment readings.
| Information Ratio | -0.11 | |||
| Maximum Drawdown | 18.07 | |||
| Value At Risk | -6.47 | |||
| Potential Upside | 6.51 |
IRLAB Therapeutics Market Risk Indicators Overview
Market risk indicators summarize volatility and return dispersion for IRLAB Therapeutics. The metrics rely on historical prices to describe variability over time.| Risk Adjusted Performance | -0.07 | |||
| Jensen Alpha | -0.39 | |||
| Total Risk Alpha | -0.39 | |||
| Treynor Ratio | 0.6033 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of IRLAB Therapeutics' price to converge to an average value over time is called mean reversion.
IRLAB Therapeutics Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.07 | |||
| Market Risk Adjusted Performance | 0.6133 | |||
| Mean Deviation | 2.67 | |||
| Coefficient Of Variation | -954.06 | |||
| Standard Deviation | 3.6 | |||
| Variance | 13.0 | |||
| Information Ratio | -0.11 | |||
| Jensen Alpha | -0.39 | |||
| Total Risk Alpha | -0.39 | |||
| Treynor Ratio | 0.6033 | |||
| Maximum Drawdown | 18.07 | |||
| Value At Risk | -6.47 | |||
| Potential Upside | 6.51 | |||
| Skewness | 0.1211 | |||
| Kurtosis | 0.5247 |
IRLAB Therapeutics Backtested Returns
IRLAB Therapeutics appears to exhibit a very high risk exposure over the selected 3 months investment horizon. It maintains a Sharpe Ratio of -0.0938, illustrating dispersion-adjusted losses. We identified twenty-three technical indicators influencing the company's volatility profile. Please review metrics such as market risk-adjusted performance of 0.6133, risk-adjusted performance of -0.07, and Coefficient Of Variation of -954.06 to confirm whether our risk estimates align with your expectations. The company has a beta of -0.64, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning IRLAB Therapeutics are expected to decrease at a much lower rate. During the bear market, IRLAB Therapeutics is likely to outperform the market. At this point, IRLAB Therapeutics has a negative expected return of -0.32%. Please make sure to check IRLAB Therapeutics' the relationship between the value at risk and accumulation distribution , to decide if IRLAB Therapeutics performance from the past will be repeated at some future point.
Auto-correlation | 0.51 |
Modest predictability
IRLAB Therapeutics AB exhibits modest predictability. Autocorrelation measures the degree of predictability between IRLAB Therapeutics time series from 10th of December 2025 to 24th of January 2026 and from 24th of January 2026 to 10th of March 2026. The stronger the relationship between the current interval and its lagged values, the more accurately future price behavior of IRLAB Therapeutics may be projected. A serial correlation of 0.51 indicates that about 51.0% of current IRLAB Therapeutics price fluctuations can be explained by its historical price movements.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | -0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, IRLAB Therapeutics AB reported net income of 51.78 M. This is 84.83% lower than that of the Healthcare sector and 26.08% lower than that of the Biotechnology industry. The net income for all Sweden stocks is 90.93% higher than that of the company.
IRLAB Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IRLAB Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to.IRLAB Therapeutics is currently under evaluation. in net income category among its top compatitors.
IRLAB Fundamentals
| Return On Equity | -0.28 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | -1.69 % | |||
| Operating Margin | -1.68 % | |||
| Current Valuation | 1.74 B | |||
| Shares Outstanding | 51.79 M | |||
| Shares Owned By Insiders | 38.63 % | |||
| Shares Owned By Institutions | 22.49 % | |||
| Price To Book | 6.24 X | |||
| Price To Sales | 33.49 X | |||
| Revenue | 207.78 M | |||
| Gross Profit | 126.05 M | |||
| EBITDA | 55.62 M | |||
| Net Income | 51.78 M | |||
| Cash And Equivalents | 401.9 M | |||
| Cash Per Share | 2.89 X | |||
| Total Debt | 3.57 M | |||
| Debt To Equity | 2.90 % | |||
| Current Ratio | 9.19 X | |||
| Book Value Per Share | 6.25 X | |||
| Cash Flow From Operations | 128.64 M | |||
| Earnings Per Share | 0.81 X | |||
| Target Price | 200.0 | |||
| Number Of Employees | 31 | |||
| Beta | 0.16 | |||
| Market Capitalization | 525.71 M | |||
| Total Asset | 472.45 M | |||
| Z Score | 88.2 | |||
| Net Asset | 472.45 M |
IRLAB Therapeutics Financial Statements and Data
Core financial indicators of IRLAB Therapeutics measure operational productivity and stability. The company is currently operating at a loss. Overall market capitalization tier is small-cap. IRLAB Therapeutics is assessed in terms of its structural contribution to portfolio diversification and long-term stability.
Methodology
Unless otherwise specified, financial data for IRLAB Therapeutics AB is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. IRLAB (SE:IRLAB-A) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Income statement, balance sheet, and cash flow figures follow GAAP or IFRS conventions as reported and may be restated by the company.
Assumptions
This report is built using public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR. Normalization for analytical consistency may introduce small timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
IRLAB Therapeutics AB may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Thematic Opportunities
Explore Investment Opportunities
More Resources for IRLAB Stock Analysis
Other Information on Investing in IRLAB Stock
IRLAB Therapeutics financial ratios help frame valuation context across profits, cash flow, and enterprise value. They help compare IRLAB to other measures in a consistent way.